BiotechTube

Durvalumab + Eribulin

Phase 1Completed
0 views this week 0 watching💤 Quiet
Interest: 29/100
29
Hype Score

Development Stage

✓
Pre-clinical
2
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

HER2-Negative Metastatic Breast Cancer

Conditions

HER2-Negative Metastatic Breast Cancer, Recurrent Ovarian Cancer

Trial Timeline

May 17, 2018 → Feb 10, 2020

NCT ID
NCT03430518

About Durvalumab + Eribulin

Durvalumab + Eribulin is a phase 1 stage product being developed by Eisai for HER2-Negative Metastatic Breast Cancer. The current trial status is completed. This product is registered under clinical trial identifier NCT03430518. Target conditions include HER2-Negative Metastatic Breast Cancer, Recurrent Ovarian Cancer.

What happened to similar drugs?

1 of 8 similar drugs in HER2-Negative Metastatic Breast Cancer were approved

Approved (1) Terminated (0) Active (7)
🔄E7389 (Eribulin Mesylate) + Vinorelbine injectionEisaiPhase 3
🔄Fluzoparib; Apatinib + Fluzoparib + Physician's choice chemotherapyJiangsu Hengrui MedicinePhase 3
🔄AZD9833 + AZD9833 Placebo + Anastrozole + Anastrozole placebo + Letrozole + Letrozole placebo + Palbociclib + Abemaciclib + Luteinizing hormone-releasing hormone (LHRH) agonist + RibociclibAstraZenecaPhase 3
🔄AZD9833 + Anastrozole + Anastrozole placebo + AZD9833 placebo + Palbociclib + Luteinizing hormone-releasing hormone (LHRH) agonistAstraZenecaPhase 3
✅Zoledronic acid + Standard TherapyNovartisApproved
🔄Giredestrant + Giredestrant-matched Placebo + Letrozole + Letrozole-matched Placebo + Palbociclib + LHRH AgonistRochePhase 3
🔄Giredestrant + Fulvestrant + Abemaciclib + Palbociclib + Ribociclib + LHRH AgonistRochePhase 3

Hype Score Breakdown

Clinical
6
Activity
8
Company
15
Novelty
0
Community
0

Clinical Trials (1)

NCT IDPhaseStatus
NCT03430518Phase 1Completed

Competing Products

19 competing products in HER2-Negative Metastatic Breast Cancer

See all competitors
ProductCompanyStageHype Score
E7389 (Eribulin Mesylate) + Vinorelbine injectionEisaiPhase 3
40
Fluzoparib; Apatinib + Fluzoparib + Physician's choice chemotherapyJiangsu Hengrui MedicinePhase 3
36
AZD9833 + AZD9833 Placebo + Anastrozole + Anastrozole placebo + Letrozole + Letrozole placebo + Palbociclib + Abemaciclib + Luteinizing hormone-releasing hormone (LHRH) agonist + RibociclibAstraZenecaPhase 3
44
AZD9833 + Anastrozole + Anastrozole placebo + AZD9833 placebo + Palbociclib + Luteinizing hormone-releasing hormone (LHRH) agonistAstraZenecaPhase 3
44
[14C]AZD9833 Oral Solution, 75 mgAstraZenecaPhase 1
29
AZD9833 + FulvestrantAstraZenecaPhase 2
39
AZD9833AstraZenecaPhase 2
35
PembrolizumabMerckPhase 2
39
Vinorebine, Everolimus + VinorelbineNovartisPhase 2
35
L-NMMANovartisPhase 2
42
Zoledronic acid + Standard TherapyNovartisApproved
43
LEE011 + Letrozole + Tamoxifen + Fulvestrant + goserelinNovartisPhase 1
29
Giredestrant + Giredestrant-matched Placebo + Letrozole + Letrozole-matched Placebo + Palbociclib + LHRH AgonistRochePhase 3
44
Giredestrant + Fulvestrant or an Aromatase Inhibitor (Physician Choice) + LHRH AgonistRochePhase 2
39
Giredestrant + Fulvestrant + Abemaciclib + Palbociclib + Ribociclib + LHRH AgonistRochePhase 3
47
Capecitabine + Carboplatin + Cisplatin + Sacituzumab govitecanGilead SciencesPhase 3
44
Non-Investigational Antibody-Drug Conjugates (ADC)Gilead SciencesPre-clinical
33
PLD Chemotherapy + CDX-1140 + CDX-301Celldex TherapeuticsPhase 1
30
ADG106 + Doxorubicin + Cyclophosphamide + PaclitaxelAdagenePhase 1/2
26